Franciscus A. G. M. Verwiel
Independent DirectorDr. Franciscus A. G. M. Verwiel, M.B.A., M.D. also known was Frank, is Director of Capsida Biotherapeutics, Inc. He has been an Independent Director at Bavarian Nordic A/S since April 19, 2016. Dr. Verwiel serves as a Director at Capsida Biotherapeutics Inc. Dr. Verwiel served as the Chief Executive Officer of Axcan Pharma US, Inc. since February 28, 2011. Dr. Verwiel served as the Chief Executive Officer and President of Aptalis Pharma Inc. from July 11, 2005 to 2014. He has also served as chairman of the board of Avidicure, a privately held biopharmaceutical company, since July 2022. He served as the Chief Executive Officer and President of Axcan Intermediate Holdings Inc. Dr. Verwiel served as Chief Executive Officer and President of Aptalis Holdings Inc. since July 2005 and Aptalis Pharma Canada ULC since July 11, 2005. He joined Aptalis Pharma in 2005. As President and Chief Executive Officer of Aptalis, he defined and implemented a strategy to achieve Aptalis' vision to become the reference GI specialty pharma company and leveraged Aptalis' assets to more effectively position in its targeted field of gastroenterology. He has extensive strategic, operational and international expertise in the biotechnology and pharmaceutical industries and over a decade of industry board experience. He possesses significant biotech and pharmaceutical experience. He served as Vice President, Hypertension, Worldwide Human Health Marketing of Merck & Co., Inc. and served as a Leader of Merck's Worldwide Hypertension Business Strategy Team. He joined Merck in 1996 and served as its Executive Director of the Hospital and Specialty Products Group targeting specialists in five core areas, including gastroenterology and was responsible for global marketing initiatives for these areas. In parallel, Dr. Verwiel served as Leader for the Worldwide Business Strategy Team on Ophthalmics of Merck. Since 1997, he served as Managing Director, The Netherlands of Merck and introduced many new products resulting in significant growth in operations. Dr. Verwiel was also Managing Director of Merck's Dutch subsidiary and manufacturing operations. From 1988 to 1996, Dr. Verwiel worked with Servier Laboratories in Europe in various executive positions. He also served as the General Manager of Merck Sharpe Dohme’s operations in the Netherlands. He served as Area Director of Servier Central/Western European operations that included Germany, Austria, Switzerland, The Netherlands, Belgium and Luxembourg. He had been the Independent Chairperson at ObsEva SA since December 2016 until May 18, 2022. Dr. Verwiel had been an Independent Director at ObsEva SA since March 24, 2016 until May 18, 2022. He had been a Director of Achillion Pharmaceuticals, Inc. until January 28, 2020. He served as Director of AveXis, Inc. from December 2015 to May 15, 2018. He serves as Independent Director of Intellia Therapeutics Inc since July 2017 and has been its Independent Chairman of the Board since February 2020. He was Observer of The Board at Bavarian Nordic A/S since August 2015. He was a Director of Aptalis Pharma Inc. since 2005. He serves as a Director of Aptalis MidCo Inc. Dr. Verwiel served as a Director of Aptalis Pharma Canada ULC since February 2008. He served as a Director of InterMune, Inc. since March 27, 2012 until September 29, 2014. He served as a Director of Aptalis Holdings, Inc. since February, 2008. He served as Director at Biotechnology Industry Organisation from 2013 to 2014. He holds Medical Doctor (M.D.) and Master of Medicine degrees from Erasmus University in Rotterdam, the Netherlands. Dr. Verwiel also attended Institut Européen d'Administration des Affaires (INSEAD) in Fontainebleau, France, where he obtained a Master of Business Administration degree.
Positions
- Company NameBavarian Nordic A/SStock CodeBVNRYPositionIndependent DirectorColleagues
- HJHenrik JuuelCFO & Executive VP
- ALAnne Louise EberhardIndependent Chair
- TSTarja StenvallPresident & CEO
- RTRussell ThirskExecutive VP & COO
- NSNicole SeroffVice President Corporate Communications
- JMJean-Christophe MayExecutive VP & Chief Commercial Officer
- HHHeidi HunterIndependent Vice Chairman of the Board
- HMHans Martin SmithIndependent Director
- FAFranciscus A. G. M. VerwielIndependent Director
- AGAnja GjolEmployee-Elected Member of the Board
- Company NameIntellia Therapeutics, Inc.Stock CodeNTLAPositionIndependent Chairman of the BoardColleagues
- JMJohn M. LeonardPresident, CEO & Director
- EJEdward J. DulacExecutive VP, CFO & Treasurer
- BSBirgit SchultesExecutive VP & Chief Scientific Officer
- JEJames E. BastaExecutive VP, General Counsel & Corporate Secretary
- RERachel E. HaurwitzCo-Founder
- JAJennifer A. DoudnaFounder & Member of Scientific Advisor Board
- DJDerrick J. RossiFounder & Member of Scientific Advisor Board
- RBRodolphe BarrangouFounder & Member of Scientific Advisor Board
